Cousin, Sophie
Guégan, Jean-Philippe
Shitara, Kohei
Palmieri, Lola Jade
Metges, Jean Philippe
Pernot, Simon
Fukuoka, Shota
Koyama, Shohei
Nishikawa, Hiroyoshi
Bellera, Carine A.
Adenis, Antoine
Gomez-Roca, Carlos A.
Cassier, Philippe Alexandre
Hollebecque, Antoine
Cantarel, Coralie
Kind, Michèle
Soubeyran, Isabelle
Vanhersecke, Lucile
Bessede, Alban
Italiano, Antoine
Funding for this research was provided by:
Bayer (REGOMUNE)
Association pour la recherche contre le cancer (REGOMUNE)
Article History
Received: 19 July 2024
Accepted: 16 August 2024
First Online: 13 September 2024
Declarations
:
: AB and JPG: Employees of Immusmol/Explicyte. AI: Received research grants from Astra Zeneca, Bayer, BMS, Chugai, Merck, MSD, Pharmamar, Novartis, Roche, and received personal fees from BMS, MSD, Merck, Roche, Epizyme, Bayer, Lilly, Roche, and Springworks. The other authors have nothing to disclose.
: This study was approved by a Central Institutional Review Board (Comité de Protection des Personnes Sud-Est II, Lyon, France), according to good clinical practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.